Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma

Xin Zhang1,2 · Tim Zegar1,2 · Anais Lucas3,4,5 · Chevaun Morrison-Smith6 · Tatiana Knox6 · Christopher A. French6 · Stefan Knapp3,4,5 · Susanne Müller3,4 · Jens T. Siveke1,2

Received: 8 October 2019 / Revised: 8 April 2020 / Accepted: 9 April 2020 / Published online: 4 May 2020
© The Author(s) 2020. This article is published with open access

Abstract
Nuclear protein of the testis (NUT) midline carcinoma (NMC), is a rare and highly aggressive form of undifferentiated squamous cell carcinoma. NMC is molecularly characterized by chromosomal rearrangement of the NUT gene to another gene, most commonly the bromodomain and extraterminal domain (BET) gene BRD4, forming the BRD4-NUT fusion oncogene. Therefore, inhibiting BRD4-NUT oncogenic function directly by BET inhibitors represents an attractive therapeutic approach but toxicity may limit the use of pan-BET inhibitors treating this cancer. We thus performed a drug screening approach using a library consisting of epigenetic compounds and ‘Donated Chemical Probes’ collated by the Structural Genomics Consortium (SGC) and identified the p300/CBP HAT inhibitor A-485, in addition to the well-known BET inhibitor JQ1, to be the most active candidate for NMC treatment. In contrast to JQ1, A-485 was selectively potent in NMC compared to other cell lines tested. Mechanistically, A-485 inhibited p300-mediated histone acetylation, leading to disruption of BRD4-NUT binding to hyperacetylated megadomains. Consistently, BRD4-NUT megadomain-associated genes MYC, CCAT1 and TP63 were downregulated by A-485. A-485 strongly induced squamous differentiation, cell cycle arrest and apoptosis. Combined inhibition of p300/CBP and BET showed synergistic effects. In summary, we identified the p300/CBP HAT domain as a putative therapeutic target in highly therapy-resistant NMC.

Introduction

Nuclear protein of the testis (NUT) midline carcinoma (NMC) is defined by chromosomal rearrangement of the nuclear protein of the testis (NUT) gene on chromosome 15q14 mainly arising in midline structures, such as head, neck and mediastinum. In ~70% of NMCs, most of the coding sequence of NUT is fused to BRD4, creating a BRD4-NUT oncogene [1, 2]. In the BRD4-NUT fusion protein, the BRD4 moiety contains two tandem bromodomains (BD) that bind to acetyl-lysine residues on histones and the NUT moiety contains two acidic domains (AD), one of which binds to the histone acetyltransferase p300/CBP stimulating its catalytic activity [3]. Recruitment of p300/CBP leads to regional histone hyperacetylation, which further recruits BRD4-NUT in a feed-forward manner [4]. Eventually, massive acetylated chromatin regions termed ‘megadomains’ are created. BRD4-NUT megadomains drive transcription of underlying genes (e.g. MYC and TP63) that prevent differentiation and stimulate growth [4].

NMC is one of the most therapy-resistant tumors. As a major pathogenic driver of transformation, BRD4-NUT...
represents a rationale target for NMC. In preclinical models, BET inhibitors (BETi) that compete with acetyl-lysines on histones for binding of BRD4 have shown anti-proliferative efficacy accompanied with squamous differentiation [5]. Exposure of NMC cells to BETi results in the loss of BRD4-NUT megadomain and downregulation of
megadomain-associated genes [4]. Several BETi have entered clinical trials and evidence of clinical activity was observed [6–8]. However, the response rate in NMC to BETi was only 20–30% and patients eventually developed resistance [6, 7]. Another concerning issue is toxicity of pan-BETi, leading most commonly to thrombocytopenia, thus limiting the usage of BETi in NMC [6, 7]. Therefore, alternative regimens or combination therapies need to be developed. In this study, we identified a p300/CBP HAT inhibitor that is selectively potent in NMC. Consistent with the location of p300/CBP in a complex with BRD4-NUT, this inhibitor disrupts BRD4-NUT megadomain and downregulates megadomain-associated genes, leading to squamous differentiation and growth arrest. Additionally, p300/CBP and BET inhibitors confer synergistic anti-tumor effects. These results implicate an alternative regimen in NMC by targeting p300/CBP as a monotherapy or combined with BETi.

Results

A-485 is selectively anti-proliferative in NMC

In order to identify potential inhibitors for NMC, we screened two libraries of highly selective and well-characterized inhibitors, so called chemical probes that have been developed by the Structural Genomics Consortium (SGC) chemical probe program (epigenetic library) or have been donated by industry (donated chemical probes, DCP). Each compound of these libraries is accompanied by its inactive structurally highly related analogues. The potency, selectivity and cellular activity of all the compounds have been extensively profiled and data are regularly updated in an online database and web resources (https://www.sgc-ffm.uni-frankfurt.de/ and https://www.thesgc.org/chemical-probes/epigenetics). The currently assembled 79 chemical probes cover diverse cellular targets such as epigenetic regulators, receptors and transporters as well as kinases [9–11] (Supplementary Fig. 1).

Next, we analyzed the NMC cell line HCC2429 and two pancreatic tumor cell lines (Patu8988T and QGP-1) to identify NMC-selective inhibitors and distinguish them from compounds of general toxicity (Fig. 1a). Among the chemical probes that showed strong anti-proliferative activity in HCC2429 cells, we identified the BETi JQ1 (P < 0.0001; Fig. 1a, b). Consistent with previous studies [12], JQ1 also showed strong activity against non-NMC cells (Fig. 1a, b). In contrast, two compounds, A-485 (P = 0.016) and BTZO-1 (P = 0.028), only showed activities in HCC2429 cells (Fig. 1a, b). A-485 was developed as a selective catalytic p300/CBP inhibitor, which has demonstrated inhibitory effects in several hematological malignancies and androgen receptor-positive prostate cancer [13]. BTZO-1, a selective inhibitor for macrophase migration inhibitory factor (MIF), was originally discovered as a cardioprotective agent [14]. However, the role of MIF in NMC remains to be established and this strategy was not pursued further in this study.

Considering the important roles of p300/CBP in NMC, we focused on A-485 for further characterization. To validate our findings, we determined the half maximal inhibitory concentration (IC50) values of A-485 across three NMC cell lines (HCC2429, 00–143 and Ty-82) and six non-NMC cell lines (Patu8988T, Patu8988S, U2OS, HepG2, M21 and COLO320DM). We found a significantly higher activity in all NMC cell lines compared to non-NMC cells (Fig. 1c). Supporting an on-target action of A-485, the inactive analogue A-486 yielded no activity in NMC cells (Fig. 1d).

A-485 impairs hyperacetylated chromatin domains and downregulates BRD4-NUT megadomain-associated genes

Because of the critical roles of p300/CBP in creating hyperacetylated chromatin domains associated with BRD4-NUT in NMC [3, 4], we explored the consequences of p300/CBP inhibition by A-485. First, we performed immunofluorescence analysis in HCC2429 cells. In DMSO-treated cells, BRD4-NUT and BRD4 expressed from wild-type allele (BRD4 wt) were co-localized with acetylated H3K27 (H3K27ac) in the distinct chromatin foci (Fig. 2a). A-485 treatment dispersed the hyperacetylated chromatin foci (Fig. 2a). Similar effects were observed in NMC cell
lines TC-797 and PER-403 (Supplementary Fig. 2A). We further observed that BRD4-NUT and BRD4 wt protein levels were decreased by A-485 (Supplementary Fig. 2B).

Previous studies demonstrated that BRD4-NUT megadomains overlap at oncogenic loci and induce abnormal expression of oncogenes (e.g. MYC, CCAT1 and TP63) in NMC [4]. CCAT1 is an enhancer RNA upstream of MYC locus [15], and CCAT1 and MYC share one BRD4-NUT megadomain [4]. We assumed that p300/CBP inhibition could impair BRD4-NUT binding at these oncogenic loci.
Fig. 2 A-485 impairs hyperacetylated chromatin domains and downregulates BRD4-NUT megadomain-associated genes. a Immunofluorescence detection of H3K27ac, BRD4-NUT and BRD4 wt proteins in HCC2429 cells incubated with 1 µM A-485 or DMSO for 3 days. Scale bar = 10 µm. b Chromatin immunoprecipitation (ChIP) analysis of H3K27ac and BRD4-NUT at the MYC promoter and TP63 enhancer regions in HCC2429 cells incubated with 1 µM A-485 or DMSO for 3 days. Chromatin was precipitated with normal rabbit IgG (IgG as control), H3K27ac and NUT antibodies. Precipitated chromatin was analyzed using qPCR and presented as fold enrichment to IgG control. Mean ± SEM from four independent experiments, **P ≤ 0.01, *P ≤ 0.05. c Quantitative RT-PCR analysis of MYC, CCAT1 and TP63 genes and (d) immunoblot analysis of H3K27ac and MYC proteins in HCC2429 cells incubated with A-485 at indicated concentrations for 48 h. Mean ± SEM from three independent experiments, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05; n.s., not significant.

due to the diminished acetylated histone. To confirm this, we performed chromatin immunoprecipitation. Indeed, we observed diminished H3K27ac and BRD4-NUT levels at the MYC promoter and TP63 enhancer regions in A-485-treated HCC2429 cells (Fig. 2b). Consistently, MYC, CCAT1 and TP63 mRNA levels were significantly repressed by A-485 at a very early time point (6 h, Fig. 2c), suggesting a direct effect of A-485 on the expression of these genes. Similar effects were observed in TC-797 and PER-403 cells (Supplementary Fig. 3A). MYC protein levels were also reduced in A-485-treated HCC2429 cells (Fig. 2d).

To further elucidate the specific role of A-485 on p300/CBP, we performed p300/CBP loss-of-function experiment. The siRNAs showed moderate repression of p300 and CBP mRNA levels respectively (Supplementary Fig. 3B). Since A-485 targets the HAT domain of both p300 and CBP, we combined p300 and CBP siRNAs for the knockdown experiment to maximally phenocopy A-485. In agreement with A-485, double knockdown of p300/CBP also downregulated MYC, CCAT1 and TP63 mRNA levels supporting target-specific effects of A-485 (Supplementary Fig. 3C). These results indicate that p300/CBP inhibition by A-485 efficiently impairs BRD4-NUT oncogenic functions in NMC.

A-485 induces squamous differentiation, cell cycle arrest and apoptosis

We reasoned that if competitive inhibition of BRD4-NUT in NMC is sufficient to induce squamous differentiation [5], A-485 might also provoke differentiation by disrupting BRD4-NUT megadomains. Indeed, A-485-treated HCC2429 cells showed a differentiation phenotype, featured by flattening of cells and accumulation of pan-keratin in the cytoplasm (Fig. 3a, b). Expression analysis by quantitative RT-PCR showed induction of three canonical squamous tissue genes (KRT10, KRT14 and TGM1) in a dose-dependent manner (Fig. 3c). C-fos, belonging to the Activation Protein-1 (AP-1) family, is an immediate-early inducible transcription factor required for normal epithelial cell differentiation [16]. Here, we also observed the induction of c-fos by A-485 (Fig. 3c). Furthermore, A-485 induced the protein levels of Involutin, a well-known differentiation marker (Fig. 3d). Differentiation phenotype was also observed in TC-797 and PER-403 cells treated with A-485 indicated by morphological changes (Supplementary Fig. 4A). Although TC-797 and PER-403 have different cells of origin and varying degrees of capacity to differentiate, their marker profiles are in most consistent with that of HCC2429 cells (Supplementary Fig. 4B, C). Consistently, p300/CBP double knockdown in HCC2429 cells also induced c-fos expression (Supplementary Fig. 4D), although the induction of squamous tissue genes (KRT10, KRT14 and TGM1) was not obvious probably due to the moderate downregulation of p300/CBP by siRNAs (Supplementary Fig. 3B). By performing chromatin immunoprecipitation analysis at the c-fos promoter region, we also observed diminished H3K27ac and BRD4-NUT enrichment upon A-485 treatment (Supplementary Fig. 5). It would be interesting to further dissect the mechanism of de-repression of differentiation gene by A-485.

In NMC cells, differentiation was shown to be accompanied by cell cycle arrest [5]. Indeed, A-485 induced G1 arrest in HCC2429 cells at early time point (24 h, Fig. 3e). Moreover, elevated levels of cleaved caspase-3 at later time points (48 and 72 h) indicated apoptosis induction by A-485 (Fig. 3f).

P300/CBP and BET inhibition have synergistic effects in NMC

Because P300/CBP and BRD4-NUT co-localize in hyperacetylated chromatin foci in NMC, we assessed if combination of p300/CBP and BET inhibitors would lead to synergistic anti-proliferative effects. We tested 9 different concentrations of A-485 ranging from 3.91 nM to 1 µM in combination with 5 different concentrations of JQ1 ranging from 6.25 to 100 nM for HCC2429 cells. After 72 h incubation, cell viability assays were performed and the synergistic effects were evaluated using SynergyFinder [17]. Combined treatment of A-485 and JQ1 showed strong synergy (ZIP synergy score 13.514, Fig. 4a). We also tested combined treatment in a non-NMC cell line Patu8988S and still observed an albeit smaller synergistic effect (ZIP synergy score 7.531, Supplementary Fig. 6), arguing that combined inhibition of p300/CBP and BET may be synergistic beyond NMC cells.

To further explore this synergistic effect, transcriptomic profiling was performed in HCC2429 cells incubated with A-485 and JQ1 alone or combined at concentrations of 1/3
of cellular IC$_{50}$ values for 8 h to evaluate the primary transcriptional effect of the inhibitors. Only 149 and 71 genes were affected by A-485 and JQ1 respectively (Fig. 4b, c), but combined treatment differentially regulated more genes (518 genes, Fig. 4b, c). To obtain insight into the gene expression patterns, we performed gene set
enrichment analysis (GSEA). In combination-treated samples, the p53 pathway and apoptosis were among the most significantly enriched pathways (Fig. 4d), which probably contribute to the observed synergistic effects. Furthermore, gene sets for MYC targets and Wnt/β-catenin signaling that support tumor cell growth and inhibit differentiation were significantly downregulated (Fig. 4d). Validating the above findings, immunoblot analysis showed enhanced cleaved caspase-3 by combined treatment (Fig. 4e), indicating induced apoptosis. Consistently, combined treatment, but not single treatment with sub-optimal concentrations, strongly inhibited colony formation (Fig. 4f and Supplementary Fig. 7A). Moreover, at concentrations below the IC50 values for the single agents, only combined treatment induced squamous differentiation (Fig. 4g and Supplementary Fig. 7B).

Discussion

We identified the p300/CBP HAT inhibitor A-485 to be highly potent in NMC but not in tested cell lines derived from other tumor entities. Our chemical probe library also included two p300/CBP bromodomain inhibitors (ICBP112 and SGC-CBP30) [18, 19]. However, both p300/CBP bromodomain inhibitors showed no or only marginally inhibitory effects on NMC cells raising the question if the bromodomain of p300/CBP is dispensable for its oncogenic function in NMC. In general, the bromodomain is required for p300/CBP to serve as acetyl-lysine binding module tethering the HAT activity to defined chromatin sites to achieve highly specific histone acetylation and transcriptional activation [20, 21]. In NMC, BRD4-NUT binds to acetylated chromatin through its bromodomains and provides a platform for the recruitment of p300/CBP and the stimulation of its HAT activity [3]. Moreover, the bromodomain of p300/CBP is not required for the direct interaction between p300/CBP and BRD4-NUT [3]. Therefore, we reasoned that the bromodomain might be dispensable for chromatin binding of p300/CBP in NMC. However, whether the bromodomain affects p300/CBP HAT activities in NMC is unknown. Further work will be required to compare the effects of the p300/CBP HAT and bromodomain inhibition to develop the most potent p300/CBP inhibitors.

NMC, one of the most lethal solid tumors, responds poorly to chemo- and radiotherapy. Since the discovery of BET proteins in the tumorigenesis of NMC, current efforts focus on targeting the causative oncoprotein BET. The main targets of the pan-BETi developed so far include BRD2, BRD3 and BRD4, which are ubiquitously expressed in tissues. Given the importance of BET proteins in the basal transcription machinery, BETi inevitably affect normal cell functions. Thrombocytopenia, fatigue, gastrointestinal symptoms, and hyperbilirubinemia are among the dose-limiting side effects reported in patients treated with BETi [7]. Pan-BETi was also reported to have activity for bromodomain testis-specific protein (BRDT), causing testicular atrophy and reversible infertility [22]. Compared to the activity of BETi across broad tumor types, p300/CBP inhibitors selectively target lineage-specific tumors [13]. Moreover, transcriptional profiling of human T cells and one prostate cancer cell line after treatment of p300/CBP inhibitors revealed significantly fewer altered genes than observed with BETi [19, 23]. Thus, p300/CBP inhibition is an alternative therapeutic strategy that potentially leads to fewer adverse events than the broadly acting BETi.

In clinical trials of BETi, only a small fraction of NMC patients responded and eventually relapsed during treatment [6, 7]. Thus, the development of BETi faces the challenges of how to enhance the sensitivity of patients and how to overcome resistance. Others [18, 23] and our study discovered that combination of p300/CBP and BETi results in a highly synergistic inhibitory effect in several tumor types. Furthermore, BETi-resistant cells continue to respond to the p300/CBP inhibitor [23]. We propose that combination therapy using both p300/CBP and BET inhibitors may be necessary to sensitize patient and overcome BETi resistance. Our efforts in exploring the molecular mechanisms of this synergistic effect in NMC discovered that combined p300/CBP and BET inhibitors significantly downregulate Wnt/β-catenin signaling. Interestingly, one study in human and mouse leukemia cells demonstrated that increased Wnt/β-catenin signaling contributes to the resistance to BETi and negative regulation of this pathway restores the sensitivity [24]. Recently, a dual inhibitor of both p300/CBP and BET showed promising anti-tumor effect in prostate cancer [25, 26]. Thus, combined p300/CBP and BET inhibition may be a rational and conceivable targeting approach in NMC and other tumor types.
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma

A. ZIP synergy score: 13.815

B. Hierarchical Clustering

C. J+A

D. P53 pathway

E. MYC targets

F. Wnt/β catenin signaling

G. KRT10

H. KRT14

I. TGM1

J. c-fos

K. Cleaved Caspase-3

L. β actin

M. KRT10

N. KRT14

O. TGM1

P. c-fos

Q. Normalized mRNA levels

R. n.s.

S. pentastar2/pentastar2/pentastar2

T. DMSO

U. 50nM JQ1

V. 250nM A-485

W. J+A

X. Cleaved Caspase-3

Y. β actin

Z. KRT10

[Image 97x162 to 507x732]
Materials and Methods

Cell culture

NMC cell lines HCC2429 [27], Ty-82 [28], 00–143 [29], TC-797 [30], PER-403 [31] and the pancreatic tumor cell line QGP-1 [32] have been described. HCC2429, Ty-82 and 00–143 were kindly provided from Lead Discovery Center GmbH (Dortmund, Germany). The pancreatic tumor cell line Patu8988T was from the American Type Culture Collection.

Data availability

Microarray data are available through ArrayExpress under the accession code E-MTAB-8955.

Acknowledgements

We are grateful for support by the SGC, a registered charity (no. 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada (OGI-055), Innovative Medicines Initiative (EU/EFFP/A) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust. JTS and SK are supported by the German Cancer Aid (grant no. 70112505; PIPAC consortium). JTS is supported by the German Cancer Consortium (DKTK) and the Deutsche Forschungsgemeinschaft (DFG) through grant SI1549/3–1 (Clinical Research Unit KFO337) and Collaborative Research Center SFB824 (project C4). Open access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Luer SC, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773–9.

2. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA, BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63:304–7.

3. Reynold N, Schwartz BE, Delvecchio M, Sadowski K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010;29:2943–52.

4. Alekseyenko AA, Walsh EM, Xiong X, Grayson AR, Hsi PT, Kharchenko PV, et al. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev. 2015;29:1507–23.

5. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–73.

6. Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, et al. Clinical response of carcinomas harboring the brd4-nut oncprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 2016;6:492–500.

7. Fisher PJ, Piaha-Paul SA, French CA, Harward S, Ferron-Brady G, Wu Y, et al. Abstract CT014: GSK5255762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part I of a phase II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers. Cancer Res. 2016;76:CT014.

8. Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36:3007–14.

9. Scheer S, Ackllo S, Medina TS, Schapira M, Li F, Ward JA, et al. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nat Commun. 2019;10:1915.

10. Wu Q, Heidenreich D, Zhou S, Ackllo S, Kramer A, Nakka K, et al. A chemical toolbox for the study of bromodomains and epigenetic signaling. Nat Commun. 2019;10:1915.

11. Muller S, Ackllo S, Arrowsmith CH, Bausen M, Baryza JL, Blagg J, et al. Donated chemical probes for open science. eLife. 2018;7:e34311.

12. Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8:24–36.

13. Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300/CRB inhibitor that targets lineage-specific tumours. Nature. 2017;550:128–32.
14. Kimura H, Sato Y, Tajima Y, Suzuki H, Yukitake H, Imaeda T, et al. BTZO-1, a cardioprotective agent, reveals that macrophage migration inhibitory factor regulates ARE-mediated gene expression. Chem Biol. 2010;17:1282–94.

15. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24:513–31.

16. Yan J, Diaz J, Jiao J, Wang R, You J. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. J Biol Chem. 2011;286:27663–75.

17. Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinforma (Oxf, Engl). 2017;33:2413–5.

18. Picauil S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, et al. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer Res. 2015;75:5106–19.

19. Hammitzsch A, Tallant C, Fedorov O, O’Mahony A, Brennan PE, Hay DA, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci USA. 2015;112:10768–73.

20. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399:491–6.

21. Syntichaki P, Topalidou I, Thireos G. The Gcn5 bromodomain co-ordinates nucleosome remodelling. Nature. 2000;404:414–7.

22. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150:673–84.

23. Brooks N, Prosser A, Young B, Gaughan L, Elvin P, Pegg N. Abstract 3826: CCS1477, a potent and selective p300/CBP bromodomain inhibitor, is targeted & differentiated from BET inhibitors in prostate cancer cell lines in vitro. Cancer Res. 2019;79:3826.

24. Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525:538–42.

25. Giles F, Witcher M, Brown B. NEO2734 - A novel potent oral dual BET and P300/CBP inhibitor. Ann Oncol. 2018;29:279–416.

26. Yan Y, Wang D, Ma J, Pang X, Lin D, Giles F, et al. Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer. J Clin Oncol. 2019;37:62–62.

27. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Gonzalez A, Gazdar AF, et al. Cloned fusion product from a rare t(15;19) (q13.2;p13.1) inhibit S phase in vitro. J Med Genet. 2005;42:558–64.

28. Kuzume T, Kubonishi I, Takeuchi S, Takeuchi T, Isawa J, Sonobe H, et al. Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality. Int J Cancer. 1992;50:259–64.

29. French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, Dal Cin P, et al. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am J Pathol. 2001;159:1987–92.

30. Toretsky JA, Jenson J, Sun CC, Eskenazi AE, Campbell A, Hunger SP, et al. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol. 2003;26:300–6.

31. Kees UR, Mulcahy MT, Willoughby ML. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol. 1991;13:459–64.

32. Igiuchi H, Hayashi I, Kono A. A somatostatin-secreting cell line established from a human pancreatic islet cell carcinoma (somatostatinoma): release experiment and immunohistochemical study. Cancer Res. 1990;50:3691–3.